Introduction
============

Thoracic and lumbar spine trauma (TLST) usually results from a high-energy injury and is frequently associated with chest and abdominal injuries \[[@b1-asj-2018-0125]\]. Mechanically unstable spinal injuries are commonly noted following severe spine trauma, and they often require surgical stabilization due to a high risk of neurological decline \[[@b2-asj-2018-0125]\]. Operative intervention for patients without neurological deficits should be considered if the Thoracolumbar Injury Classification and Severity (TLICS) score exceeds 4 points \[[@b3-asj-2018-0125],[@b4-asj-2018-0125]\]. Multilevel spinal fusions require a longer operative time, with significant soft tissue stripping as well as blood loss, which frequently leads to allogeneic blood transfusion \[[@b5-asj-2018-0125]\]. In particular, the economic disadvantage associated with significant iatrogenic blood loss contributes to the direct costs of blood product usage. Moreover, indirect costs, including those associated with prolonged hospitalization, are often involved in the management of this complication \[[@b6-asj-2018-0125]-[@b8-asj-2018-0125]\].

Several interventions have been used to reduce surgical blood loss and the need for transfusion, including acute normovolemic hemodilution and various blood salvaging techniques \[[@b7-asj-2018-0125],[@b8-asj-2018-0125]\]. Additionally, antifibrinolytic agents have been used in various studies to control acute hemorrhage and decrease transfusion requirements in patients undergoing surgical treatment \[[@b5-asj-2018-0125],[@b7-asj-2018-0125],[@b9-asj-2018-0125]\]. Intravenous administration of tranexamic acid (TXA) not only reduces perioperative hemorrhage, but also minimizes the need for blood transfusion by one-third in several clinical settings, including major surgery \[[@b9-asj-2018-0125]\]. This is especially important in multilevel spinal fusion procedures with instrumentation, which often require postoperative blood transfusion \[[@b10-asj-2018-0125]\]. Even though intravenous TXA has been shown to reduce excessive postoperative bleeding, it is unclear whether the effects of this drug can be escalated, potentially resulting in thromboembolic events and cardiovascular complications (e.g., pulmonary embolism, deep venous thrombosis, and myocardial infarction) \[[@b11-asj-2018-0125]\]. Topical TXA might enhance patient safety, as similar effects via an intravenous route were reported in another study \[[@b12-asj-2018-0125]\].

The present study examined different techniques of topical TXA application in spinal surgery compared with normal saline placebo. The purpose was to evaluate the effect of topically applied 1 g TXA on postoperative packed red cells (PRC) transfusion and blood loss in neurologically intact patients with TLST.

Materials and Methods
=====================

1. Patient sample and data collection
-------------------------------------

After ethical approval by the Institutional Review Board of Maharat Nakhon Ratchasima Hospital, patients with TLST (clinically and radiographically confirmed TLICS score ≥5 points) were evaluated at the Department of Orthopedic Surgery between May 2015 and September 2016. All patients with spinal trauma who were admitted to the Maharat Nakhon Ratchasima Hospital during this period were consecutively assessed for inclusion and exclusion criteria ([Table 1](#t1-asj-2018-0125){ref-type="table"}). Neurological function was scored according to the standard protocol established by the American Spinal Injury Association. Additional clinical parameters collected included the patient's age, sex, body mass index, TLICS score, mechanism of injury, and American Society of Anesthesiologists physical status and radiographic features. Before study enrollment, each patient underwent plain radiography of the affected regions in the anteroposterior and lateral projections. All patients also underwent a preoperative computed tomographic scan of the thoracic and lumbar areas with multiplanar reconstructions. The patients were educated about the symptoms of thrombotic and embolic disorders as well as treatment-related side effects from the use of TXA. The procedure was explained to all participants, who gave their voluntary written informed consent. The surgeons and participants did not know to which group each patient belonged.

The study was conducted in accordance with the consolidated standards of reporting trials statement for randomized controlled trials. This was a double-blinded, prospective, randomized, controlled clinical trial to compare topically applied TXA and placebo in TLST patients without neurological deficits. Enrolled participants were assigned to one of the two treatment groups at a 1:1 ratio using blocked randomization. A four-number-per block randomization was performed using random numbers generated by statistical software, and the allocations were concealed in opaque envelopes. According to the results of a previous retrospective study \[[@b13-asj-2018-0125]\], a sample size of at least 28 patients per group was needed to detect a reduction in postoperative transfusion rate from 44.7% in the matched control group to 11.4% in the deferred treatment group with a two-sided significance level of 5% and a power of 80%. Thus, allowing for a 7% dropout rate, a minimum of 30 patients per group was required.

After operating with long-segment instrumentation (two levels above and below the injured level or two levels above and one level below with using a pedicle screw at the fractured level), instrumented stabilization was achieved using pedicle screw fixation (Zenius; Medyssey, Jecheon, Korea) without decompression ([Figs. 1](#f1-asj-2018-0125){ref-type="fig"}, [2](#f2-asj-2018-0125){ref-type="fig"}). Posterior spinal fusion was performed using an autologous local bone graft. The operations were performed by a single surgeon (W.S.).

At the end of the fusion operation, and after the spinal fascia was closed, an appropriate solution was injected into the posterior surface of the decorticated laminae via the drain tube (Redon-Drain; Pfm Medical Mepro GmbH, Nonnweiler-Otzenhausen, Germany). In patients receiving topical TXA, the solution containing 1 g of TXA (Transamin; OLIC Thailand, Ayutthaya, Thailand), yielding a total volume of 20 mL (250 mg/5 mL), was applied to the site of surgery. The drain bottle was then connected to the drain tube, which was clamped for 2 hours. The same volume of normal saline was given to the control group, and clamping was performed using the same technique as in the experimental group. A research anesthesiologist nurse prepared the treatment medications and placebo, which were identical in appearance. Even after application of the experimental solution, the investigators did not know the group assignments.

The same postoperative protocols were followed in each group except for drainage tube removal. The drain was removed at no more than 5 days after the surgical procedure or when the drainage output had been less than 50 mL for the previous 24 hours. A complete blood count was performed at 2, 24, and 48 hours postoperatively. Symptoms (such as fatigue, headache, or dizziness) and signs (such as tachycardia, conjunctival pallor, shortness of breath, or tachypnea) of declining hemoglobin (Hb) levels were assessed and used as an adjunct to laboratory abnormalities.

The primary outcome was requirement for PRC transfusion postoperatively prior to discharge home. The transfusion criteria followed the clinical practice guideline recommending transfusion if postoperative Hb was ≤8 g/dL or postoperative Hb was \<10 g/dL with anemic symptoms \[[@b14-asj-2018-0125]\]. The secondary outcomes were total drainage volume, time to drain removal, and duration of postoperative hospitalization. Severity of pain was assessed using Visual Analog Scale (VAS). Data on adverse events, complications, and their effect on spinal fusion were also collected in the early postoperative course and during a follow-up period of at least 12 months.

2. Ethical approval and consent to participate
----------------------------------------------

Ethics approval was obtained from the Institutional Review Board, Maharat Nakhon Ratchasima Hospital Ethics Committee (IRB approval no., MNRH IRB 102/2015). All participants provided informed consent. The study was retrospectively registered at Clinicaltrials.in.th (Identifier: TCTR20160412001) on April 11, 2016.

3. Statistical analysis
-----------------------

All statistical analyses were conducted using IBM SPSS software for Windows ver. 23.0 (IBM Corp., Armonk, NY, USA). Variables were expressed as medians and interquartile ranges (IQR), frequencies and percentages, or means and standard deviations, as appropriate. The nonparametric Mann--Whitney *U*-test was used for non-normally distributed data. The chi-square test was used for testing relationships between categorical variables to examine proportional differences. The two-sample *t*-test was performed to examine mean differences between groups. The proportions of patients who received PRC transfusions are summarized as percentages, and 95% confidence intervals (CI) are specified. A *p*-value \<0.05 was considered to indicate statistical significance.

Results
=======

Sixty participants were recruited and randomized to receive the study medication or placebo. The study group comprised 57 patients, including 29 in the topical TXA group and 28 in the control group ([Fig. 3](#f3-asj-2018-0125){ref-type="fig"}). Three participants dropped out for health reasons (n=2) or an adverse event unrelated to the treatment (n=1). Two patients in the control group developed severe physical illnesses that were judged to be incompatible with the study aims, and one patient in the topical TXA group was excluded because of an unintentionally removed drain (day 1). The groups were similar at baseline ([Table 2](#t2-asj-2018-0125){ref-type="table"}).

No differences were found in preoperative and intraoperative transfusion rates between the topical TXA group and the control group (20.7% versus 17.9%; 95% CI, 0.40 to 3.69; *p*=0.79 and 13.8% versus 25.0%; 95% CI, 0.18 to 1.68; *p*=0.28, respectively). The rate of postoperative PRC transfusion was significantly lower in the topical TXA group than in the control group (13.8% versus 39.3%; relative risk, 0.35; 95% CI, 0.13 to 0.97; *p*=0.03).

The mean total drainage volume was significantly less in the topical TXA group than in the control group (246.7±125 mL versus 445.7±211.1 mL, *p*\<0.01). The median drainage output during the first 24 hours and the subsequent 24- to 48-hour and 48- to 72-hour periods was also significantly less in the topical TXA group than in the control group (200 mL versus 315 mL; IQR, 100--250 mL versus 215--407.5 mL; *p*\<0.01; 50 mL versus 75 mL; IQR, 20--90 mL versus 52.5--107.5 mL; *p*=0.02, and 0 mL versus 5 mL; IQR, 0--5 mL versus 0--37.5 mL; *p*=0.02, respectively) ([Fig. 4](#f4-asj-2018-0125){ref-type="fig"}). No difference was found in the mean preoperative Hb level on the day of operation between the topical TXA group and the control group (12.5±1.7 g/dL versus 11.9±1.5 g/dL; range, 8--15 g/dL versus 7.5--15 g/dL; *p*=0.16), but the topical TXA group had higher mean Hb levels than the control group (patients who had received a postoperative transfusion were not included in the analysis) at 2, 24, and 48 hours postoperatively (12.2±1.8 g/dL versus 11.2±1.6 g/dL; range, 8--15 g/dL versus 7.9--15 g/dL; *p*=0.04; 11.7±1.5 g/dL versus 10.6±1.5 g/dL; range, 9--14.9 g/dL versus 7.6--13.8 g/dL; *p*=0.01, and 11.6±1.3 g/dL versus 10.7±1.2 g/dL; range, 9--14.5 g/dL versus 7.8--13.3 g/dL; *p*=0.04, respectively). The mean number of days to drain removal in the topical TXA group was 2.8±0.9 days, compared with 3.2±0.8 days in the control group, a significant difference (*p*=0.04). The mean duration of postoperative hospitalization was significantly shorter in the topical TXA group than in the control group (7.7±2.7 days versus 10.4±6.2 days, *p*=0.03). The difference between the two groups in pain score, as measured by VAS preoperatively and at any time period postoperatively, was nonsignificant (all p\>0.05) ([Table 3](#t3-asj-2018-0125){ref-type="table"}).

Posterior fusion was achieved within 12 months in all cases, and there was no failure of instrumentation according to radiographs during an average follow-up of 27.5±4.7 months (range, 20.3 to 35.6 months). Regarding the safety outcome, the investigators found no clinical evidence of adverse events or complications up to 1 year following the procedure.

Discussion
==========

The currently available clinical data confirm that intravenous TXA during spinal surgery can reduce perioperative bleeding, but the evidence to reach a reliable conclusion regarding safety risk so far is too limited \[[@b8-asj-2018-0125]-[@b10-asj-2018-0125],[@b15-asj-2018-0125],[@b16-asj-2018-0125]\]. Myocardial infarction and systemic thromboembolic complications are rare but potentially life-threatening events in surgical patients receiving intravenous TXA \[[@b11-asj-2018-0125]\]. The theoretical concern for the risk of thromboembolism with intravenous TXA remains, which has encouraged investigations on TXA administration via a topical route.

In the field of cardiac and arthroplasty surgery, topical TXA has been introduced as an equally effective and safe alternative to intravenous TXA, especially for the prevention of postoperative bleeding events \[[@b11-asj-2018-0125],[@b12-asj-2018-0125]\]. The mechanism of topical application of TXA, a synthetic derivative of the amino acid lysine that has strong antifibrinolytic activity, is through binding to the bleeding surface, which is believed to inhibit local fibrinolysis only at the surgical field. TXA can block the enzymatic interaction of plasminogen/plasmin with fibrinogen/fibrin, thereby preventing fibrin degradation and delaying clot dissolution \[[@b17-asj-2018-0125]\].

Some trials have reported on the effect of topical TXA in spinal procedures. Krohn et al. \[[@b18-asj-2018-0125]\] reported that 500 mg of TXA added to the irrigation solution and suctioned away after 2 to 5 minutes of application significantly reduced blood loss in lumbar spinal fusion surgery by up to half. Similarly, Saberi et al. \[[@b19-asj-2018-0125]\] found that locally poured 250 mg of TXA, with a volume of 5 mL, in the epidural space of patients undergoing laminectomy significantly reduced postoperative drainage volume on the first and second days, as well as overall. The use of topical TXA in spine surgery has recently been reviewed in a meta-analysis \[[@b20-asj-2018-0125]\] of four studies of 136 patients who received TXA via an irrigation solution or a soaked absorbable gelatin sponge compared with 134 patients who received saline placebo. Luo et al. \[[@b20-asj-2018-0125]\] reported that topical TXA reduced postoperative drain output (mean difference, −157 mL; *p*\<0.01) and transfusion risk (risk difference, −0.18; *p*=0.28). The authors of the present study tried to apply a different technique for the use of topical TXA in posterior spinal fusion surgery and obtained favorable outcomes, especially in a multilevel procedure without laminectomy (mean difference in drain output, −199 mL; *p*\<0.01; risk difference for transfusion, −0.26; *p*=0.03).

The optimal dose of TXA for reduction of postoperative blood loss has not yet been established. Previous studies showed that topical application of 500 mg to 3 g of TXA reduced postoperative or total blood loss compared with placebo in patients undergoing total knee arthroplasty \[[@b21-asj-2018-0125]-[@b23-asj-2018-0125]\]. Ker et al. \[[@b9-asj-2018-0125]\] examined the data from 104 studies and found that various doses of intravenous TXA administered in randomized controlled trials had a significant effect on the amounts of intraoperative and postoperative blood loss. The reported doses of TXA in 18 randomized controlled trials (n=1,651 patients) were highly heterogeneous, ranging from 5.5 to 300 mg/kg. A dose of 1 g appeared to be sufficient for most adults, whereas no evidence emerged to support the use of high doses of TXA \[[@b9-asj-2018-0125]\]. As reported in patients undergoing cardiac surgery, Martin et al. \[[@b24-asj-2018-0125]\] noted that the use of high-dose TXA resulted in seizure rates that were at least 10-fold higher than those seen with low-dose administration. Concern about safety led the authors of the present study to undertake research using a moderate dose of TXA. However, a 1-g dose was sufficient in a four-level spinal fusion procedure, as demonstrated by the results of the present study.

The ideal technique for topical use and the optimal timing of intraoperative topical TXA application in spinal surgery have not been clearly determined. According to the pharmacodynamic and pharmacokinetic properties of TXA, the maximum plasma concentration is obtained at 30 minutes after administration, and the terminal elimination half-life is about 120 minutes \[[@b17-asj-2018-0125]\]. In the present study, 1 g of topical TXA was applied to the site of surgery via a drain tube after the spinal fascia was closed, and then the drain was clamped for 2 hours. The length of time that the drain was clamped was equal to the half-life of TXA and was sufficient for the hemostatic activity of topical TXA to be exerted before the drain was unclamped. A longer clamping period might cause more pain and might predispose to the formation of large hematomas, which sometimes require surgical removal.

The authors decided to exclude patients from the study who had neurological deficits that required decompressive surgery, for the following reasons. First, caution needs to be taken to prevent direct contact between TXA and neural tissues, because epileptic seizures were reported to develop when TXA was topically applied for surgery within or close to the central nervous system in an experimental rat model \[[@b25-asj-2018-0125]\]. Second, an association between dural tears and neurological deficits has been consistently reported in patients with spinal injuries \[[@b26-asj-2018-0125]-[@b28-asj-2018-0125]\]. For these reasons, the use of topical TXA poses a considerable risk in patients presenting with neurological deficits resulting from TLST.

There were some limitations to the present study. The extent of topical TXA tissue absorption following clamping of the drain was not quantified and should be documented by collecting samples, such as serum or plasma. Subsequent analysis of hemolytic activity should be conducted and the concentration of degradation products via the drainage tube should be measured to obtain further information about the mechanism of action and systemic absorption of topical TXA. Pulmonary arteriograms and lower extremity venograms are recommended to detect thromboembolism; however, in this study clinical assessment was used to detect complications because of the relatively high cost and invasiveness of these tools. An additional limitation of this study was the mid-term follow-up period (more than 1 year but less than 5 years), which is inadequate to monitor potential long-term complications.

Conclusions
===========

The use of topically administered 1 g of TXA (20 mL) in thoracic and lumbar spinal trauma cases undergoing a posterior fusion procedure with long-segment instrumentation effectively decreased postoperative transfusion requirements. The treatment also reduced total drainage volume, time until drain removal, and length of postoperative hospital stay.
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![A 64-year-old man fell from a height of 3 m in a building and complained of severe back pain at the thoracolumbar junction. (A) Preoperative plain film demonstrated a burst fracture of L1. (B) Sagittal computed tomography reconstruction showed a spinous process fracture on L1 and a slight widening of the facet joints (T12--L1 and L1--L2), which confirmed the diagnosis of posterior ligamentous complex involvement. (C) Postoperative plain film of the thoracolumbar spine depicting pedicle screw fixation T11--L3. (D) Well-maintained sagittal alignment at 1-year follow-up.](asj-2018-0125f1){#f1-asj-2018-0125}

![A 24-year-old woman was injured in a motor vehicle accident. On admission, the patient was neurologically intact. (A) Preoperative plain film showed a flexion-distraction injury at T12--L1 and mild superior endplate fracture of L1. (B) Axial computed tomography scan showed empty facet joints. (C) Postoperative plain film detailing a pedicle screw-instrumented spine at T11--L2. (D) Flexion and extension radiographs 1 year after the injury show satisfactory alignment.](asj-2018-0125f2){#f2-asj-2018-0125}

![Consolidated standards of reporting trials flow diagram showing the progress of study participants throughout the trial.](asj-2018-0125f3){#f3-asj-2018-0125}

![Median and interquartile range of drainage output during the first 24 hours and the subsequent 24- to 48-hour and 48- to 72-hour periods after operation.](asj-2018-0125f4){#f4-asj-2018-0125}

###### 

The inclusion and exclusion criteria

  Inclusion criteria                                                                                                                                                                                                                                      Exclusion criteria
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------
  Men and women, 18 to 70 years of age with injuries involving the thoracic or lumbar spine (Thoracolumbar Injury Classification and Severity score ≥5) undergoing long-segment instrumented poste- rior spinal fusion with local autologous bone graft   Renal insufficiency
  History of thromboembolic events (e.g., pulmonary embolism, embolic stroke, and deep venous thrombosis)                                                                                                                                                 
  No neurological deficits                                                                                                                                                                                                                                History of significant cardiovascular diseases (e.g., unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension)
  American Society of Anesthesiologists physical status class I, II, or III                                                                                                                                                                               
                                                                                                                                                                                                                                                          History of acquired defective color vision Coagulation disorder
  Gross hematuria or microhematuria                                                                                                                                                                                                                       
  Displaced laminar fracture on computed tomography axial section that might be associated with dural tears                                                                                                                                               
  Allergy to tranexamic acid                                                                                                                                                                                                                              
  Take aspirin or nonsteroidal anti-inflammatory drugs within a week before randomization and during the hospitalization                                                                                                                                  

###### 

General baseline characteristics (n=57)

  Characteristic                                           Topical tranexamic acid group (n=29)   Control group (n=28)   *p*-value
  -------------------------------------------------------- -------------------------------------- ---------------------- ------------------------------------------------------
  Age (yr)                                                 52 (33.5--55.5)                        51.5 (33.5--58.0)      0.45^[a)](#tfn1-asj-2018-0125){ref-type="table-fn"}^
  Sex                                                                                                                    0.23^[b)](#tfn2-asj-2018-0125){ref-type="table-fn"}^
   Male                                                    20 (69.1)                              15 (53.6)              
   Female                                                  9 (30.9)                               13 (46.4)              
  Body mass index (kg/m^2^)                                22.2±3.3                               22.3±3.2               0.87^[c)](#tfn3-asj-2018-0125){ref-type="table-fn"}^
  Thoracolumbar Injury Classification and Severity score                                                                 0.12^[b)](#tfn2-asj-2018-0125){ref-type="table-fn"}^
   5                                                       21 (72.4)                              26 (92.9)              
   6                                                       1 (3.5)                                \-                     
   7                                                       7 (24.1)                               2 (7.1)                
  Mechanism of injury                                                                                                    0.98^[b)](#tfn2-asj-2018-0125){ref-type="table-fn"}^
   Fall from height                                        20 (69.0)                              18 (64.3)              
   Motorcycle accident                                     4 (13.8)                               4 (14.2)               
   Motor vehicle accident                                  4 (13.8)                               5 (17.9)               
   Stuck by a heavy object                                 1 (3.4)                                1 (3.6)                
  Fractured level                                                                                                        0.29^[b)](#tfn2-asj-2018-0125){ref-type="table-fn"}^
   T11                                                     3 (10.3)                               1 (3.6)                
   T12                                                     8 (27.6)                               5 (17.9)               
   L1                                                      16 (55.2)                              16 (57.1)              
   L2                                                      2 (6.9)                                6 (21.4)               
  American Society of Anesthesiologists physical status                                                                  0.56^[b)](#tfn2-asj-2018-0125){ref-type="table-fn"}^
   1 or 2                                                  22 (75.9)                              23 (82.1)              
   3                                                       7 (24.1)                               5 (17.9)               
  Preoperative anterior body height loss (%)               49.4±14.3                              46.0±13.0              0.36^[c)](#tfn3-asj-2018-0125){ref-type="table-fn"}^
  Fracture body angle (°)                                  19.9±6.1                               20.2±8.3               0.89^[c)](#tfn3-asj-2018-0125){ref-type="table-fn"}^
  Operative time (min)                                     98.6±18.2                              91.0±18.6              0.12^[c)](#tfn3-asj-2018-0125){ref-type="table-fn"}^
  Intraoperative fluid volume (mL)                         1,753.5±365.5                          1,882.1±434.5          0.23^[c)](#tfn3-asj-2018-0125){ref-type="table-fn"}^
  Intraoperative total estimated blood loss (mL)           260.3±166.0                            265.0±146.6            0.90^[c)](#tfn3-asj-2018-0125){ref-type="table-fn"}^

Values are presented as median (interquartile range), number (%), or mean±standard deviation.

Result of Mann--Whitney *U*-test.

Result of chi-square test.

Result of two sample t -test.

###### 

Results of the data analysis for length of stay, time from injury to surgery, drain removal time, radiographic parameters, postoperative blood loss, VAS scores and follow-up duration between the topical TXA and the control group

  Variable                                      Topical TXA group (n=29)   Control group (n=28)   *p*-value
  --------------------------------------------- -------------------------- ---------------------- ------------------------------------------------------
  Length of stay (day)                          12.9±5.1                   17.3±6.5               0.00^[a)](#tfn4-asj-2018-0125){ref-type="table-fn"}^
  Time from injury to surgery (day)             5.2±3.6                    6.8±3.5                0.09^[a)](#tfn4-asj-2018-0125){ref-type="table-fn"}^
  Postoperative hospitalization (day)           7.7±2.7                    10.4±6.2               0.03^[a)](#tfn4-asj-2018-0125){ref-type="table-fn"}^
  Drain removal time (day)                      2.8±0.9                    3.2±0.8                0.04^[a)](#tfn4-asj-2018-0125){ref-type="table-fn"}^
  Postoperative anterior body height loss (%)   17.3±10.6                  15.5±12.7              0.57^[a)](#tfn4-asj-2018-0125){ref-type="table-fn"}^
  Postoperative fracture body angle (°)         10.2±4.8                   9.1±5.2                0.43^[a)](#tfn4-asj-2018-0125){ref-type="table-fn"}^
  Postoperative blood loss (mL)                                                                   
   Dressing gauze blood loss                    32.2±26.9                  43±28.1                0.14^[a)](#tfn4-asj-2018-0125){ref-type="table-fn"}^
   Drainage blood loss                          246.7±125                  445.7±211.1            0.00^[a)](#tfn4-asj-2018-0125){ref-type="table-fn"}^
   Total blood loss                             279±135.2                  488.8±223.5            0.00^[a)](#tfn4-asj-2018-0125){ref-type="table-fn"}^
  VAS                                                                                             
   VAS at 24 hr before operation                5 (4--5)                   5 (4--6)               0.52^[b)](#tfn5-asj-2018-0125){ref-type="table-fn"}^
   VAS at 24 hr after operation                 7 (6.5--8)                 7 (7--8)               0.80^[b)](#tfn5-asj-2018-0125){ref-type="table-fn"}^
   VAS at 48 hr after operation                 6 (5--8)                   5.5 (5--7)             0.23^[b)](#tfn5-asj-2018-0125){ref-type="table-fn"}^
   VAS at discharge from hospital               3 (2--5)                   3.5 (3--5.8)           0.67^[b)](#tfn5-asj-2018-0125){ref-type="table-fn"}^
  Follow-up duration (mo)                       28.1±4.6                   26.9±4.7               0.36^[b)](#tfn5-asj-2018-0125){ref-type="table-fn"}^

Values are presented as mean±standard deviation or median (interquartile range). Bold type is considered statistically significant (*p* \<0.05).

VAS, Visual Analog Scale; TXA, tranexamic acid.

Result of two sample *t*-test.

Result of Mann--Whitney *U*-test.
